pravastatin has been researched along with Hyperlipoproteinemia Type II in 103 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 11 (10.68) | 18.7374 |
| 1990's | 63 (61.17) | 18.2507 |
| 2000's | 20 (19.42) | 29.6817 |
| 2010's | 9 (8.74) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braamskamp, MJ; Hutten, BA; Kastelein, JJ; Tsimikas, S; Wiegman, A | 1 |
| Aslani, P; Ayoub, R; Gelissen, IC; Moles, R; Nguyen, HL; Tiao, DK | 1 |
| Avis, HJ; de Groot, E; Hutten, BA; Kastelein, JJ; Kusters, DM; Wiegman, A; Wijburg, FA | 1 |
| Braamskamp, MJ; Hutten, BA; Wiegman, A | 1 |
| Avis, HJ; Braamskamp, MJ; Hutten, BA; Kastelein, JJ; Kusters, DM; van Trotsenburg, AS; Wiegman, A; Wijburg, FA | 1 |
| Arnaud, L; Caillaud, A; Cariou, B; Champon, B; Idriss, S; Le May, C; Lemarchand, P; Pichelin, M; Si-Tayeb, K; Zibara, K | 1 |
| Adams-Huet, B; Ahmad, Z; Khine, H; Yuet, WC | 1 |
| Bruckert, E; Carreau, V; Girardet, JP | 1 |
| Daimon, T; Fumimoto, Y; Hayakawa, T; Ichinose, A; Komoda, H; Matsuyama, A; Moriyama, H; Moriyama, M; Okura, H; Saga, A; Soeda, M; Tani, J; Yamashita, S | 1 |
| Sinzinger, H | 1 |
| Antikainen, M; Hedman, M; Neuvonen, M; Neuvonen, PJ | 1 |
| Kastelein, JJ; Rodenburg, J; Stalenhoef, AF; Vissers, MN; Wiegman, A | 1 |
| Bakker, HD; Büller, HR; de Groot, E; Hutten, BA; Kastelein, JJ; Rodenburg, J; Sijbrands, EJ; Wiegman, A | 1 |
| Antikainen, M; Föhr, A; Hedman, M; Lappi, M; Matikainen, T; Nuutinen, M; Piippo, S | 1 |
| Angelini, G; Carson, K; George, S; Jackson, C; Johnson, J; Karanam, S; Newby, A; Williams, H | 1 |
| Riesen, WF | 1 |
| Hutten, BA; Kastelein, JJ; Koeijvoets, KC; Rodenburg, J; Sijbrands, EJ; Wiegman, A | 1 |
| Antikainen, M; Gylling, H; Hedman, M; Ketomäki, A; Miettinen, TA | 1 |
| Aukrust, P; Gullestad, L; Hutten, B; Kastelein, JJ; Ose, L; Ridker, PM; Rifai, N; Rodenburg, J; Semb, AG; Ueland, T; Vissers, MN; Wiegman, A | 1 |
| Kastelein, JJ; Miller, ER; Ridker, PM; Rodenburg, J; Tsimikas, S; Vissers, MN; Wiegman, A; Witztum, JL | 1 |
| Antikainen, M; Eichelbaum, M; Hedman, M; Holmberg, C; Kivistö, KT; Neuvonen, M; Neuvonen, PJ; Niemi, M | 1 |
| Broncel, M; Chojnowska-Jezierska, J; Duchnowicz, P; Franiak, I; Koter-Michalak, M | 1 |
| Bhasin, B; Malhotra, S; Pandhi, P; Pattanaik, S; Shafiq, N; Singh, M; Venkateshan, SP | 1 |
| Cariou, B; Costet, P; Jarnoux, AL; Kourimate, S; Krempf, M; Langhi, C; Le May, C; Nguyen, P; Ouguerram, K; Zaïr, Y | 1 |
| Hutten, BA; Kastelein, JJ; Otvos, JD; Rodenburg, J; Stroes, ES; Trip, MD; van der Graaf, A; Vissers, MN; Wiegman, A; Wijburg, FA | 1 |
| Cole, T; Lopez-Miranda, J; Ordovas, JM; Park, JS; Perez-Jimenez, F; Rodriguez, C; Schaefer, EJ | 1 |
| Kita, T; Otani, H; Tanaka, M; Yokode, M | 1 |
| Deerochanawong, C; Serirat, S | 1 |
| Berthézène, F; Chapman, MJ; Dolphin, PJ; Gardette, J; Guérin, M; Talussot, C | 1 |
| Fusegawa, Y; Goto, Y; Moriguchi, EH; Oguma, T; Shiina, Y; Tada, H; Tamachi, H; Tanabe, T; Tomoda, H | 1 |
| Pedreño, J; Ros, E; Sánchez, JL; Zambón, D | 1 |
| Devynck, MA; Le Quan Sang, KH; Levenson, J; Megnien, JL; Simon, A | 1 |
| Bowler, A; Elsegood, CL; Mamo, JC; Redgrave, TG | 1 |
| Pirich, C; Sinzinger, H | 1 |
| Vanhanen, H | 1 |
| Angelin, B; Beck, O; Berglund, L; Bröijersén, A; Eriksson, M; Hjemdahl, P; Larsson, PT | 1 |
| Connelly, PW; Davignon, J; Gagné, C; Hayden, MR; Hegele, R; Lupien, PJ; McPherson, R; Montigny, M; Roederer, G; Tan, MH | 1 |
| Branchi, A; Fasoli, A; Gugliandolo, AG; Rovellini, A; Sommariva, D | 1 |
| Baumstark, MW; Berg, A; Buxbaum, S; Herwig, J; März, W; Pohl, T; Russ, A; Ruzicka, V; Schaaf, L; Scharnagl, H | 1 |
| Mazzanti, L; Polenta, M; Rabini, RA; Signore, R; Staffolani, R; Testa, I; Tocchini, M | 1 |
| Haraki, T; Inazu, A; Kajinami, K; Kamon, N; Koizumi, I; Koizumi, J; Miyamoto, S; Takegoshi, T; Uno, Y; Yagi, K | 1 |
| De Haan, AF; Demacker, PN; Kleinveld, HA; Stalenhoef, AF | 1 |
| Angelin, B; Berglund, L; Bondjers, G; Eggertsen, G; Eriksson, M; Lindén, T; Olofsson, SO; Wiklund, O | 1 |
| Faergeman, O; Gerdes, LU; Hansen, FA; Klausen, IC; Meinertz, H | 1 |
| Aoyagi, S; Matsuzaki, M; Morikuni, C; Okada, K; Okuda, F; Ono, S; Tanaka, N; Tokisawa, I; Tomochika, Y; Wasaki, Y | 1 |
| Bakker, HD; Boelen, CC; Büller, HR; Groenemeijer, BE; Kastelein, JJ; Knipscheer, HC; van den Ende, A; van Diermen, DE | 1 |
| Colette, C; Crastes De Paulet, A; Descomps, B; Farnier, M; Feillet, C; Monnier, LH; Percheron, C | 1 |
| Campagnoli, G; Dorigotti, F; Franceschini, G; Gianfranceschi, G; Pazzucconi, F; Sirtori, CR; Sirtori, M | 1 |
| Wendelhag, I; Wiklund, O; Wikstrand, J | 1 |
| Firth, JC; Marais, AD; Mountney, J; Naoumova, RP; Rendell, NB; Taylor, GW; Thompson, GR | 1 |
| Kameda-Takemura, K; Keno, Y; Matsuzawa, Y; Nakagawa, T; Nakamura, T; Nakata, A; Nozaki, S; Tokunaga, K; Yamashita, S | 1 |
| Baldi, S; Ferrannini, E; Frascerra, S; Galetta, F; Galvan, AQ; Natali, A; Sampietro, T; Seghieri, G | 1 |
| Arpaia, G; Bonfardeci, G; Cimminiello, C; Lorena, M; Milani, M; Soncini, M | 1 |
| Ganotakis, ES; Mikhailidis, DP; Winder, AF | 1 |
| Alvarez-Sala, LA; Blázquez, E; de Oya, M; Garrido, JA; Mata, P; Ordovás, JM; Rubio, MJ | 1 |
| Braesen, JH; Gebhardt, A; Harsch, M; Lang, G; Löser, R; Niendorf, A; Reymann, A; Schliack, M | 1 |
| Higashikata, T; Inazu, A; Kajinami, K; Koizumi, J; Mabuchi, H; Yagi, K | 1 |
| Bláha, V; Brátová, M; Havel, E; Solichová, D; Zadák, Z | 1 |
| Aggeli, KI; Barbetseas, JD; Frogoudaki, AA; Lambrou, SG; Pitsavos, CE; Skoumas, IN; Stefanadis, CI; Toutouzas, PK | 1 |
| Horikoshi, H; Ito, T; Shiomi, M; Tsujita, Y; Tsukada, T | 1 |
| de Maat, MP; Gevers Leuven, JA; Kluft, C; Mohrschladt, MF; Potter van Loon, BJ | 1 |
| O'Grady, J; Schmid, P; Sinzinger, H | 1 |
| Azuma, N; Matsugane, T; Motohashi, K; Nishide, T; Nobuto, T; Suzuki, M; Yamane, S | 1 |
| Chichibu, K; Inazu, A; Kajinami, K; Kiyohar, T; Koizumi, J; Mabuchi, H | 1 |
| Lupattelli, G; Palumbo, B; Sinzinger, H | 1 |
| Homma, Y; Kobayashi, T | 1 |
| Athyros, VG; Demitriadis, DS; Kontopoulos, AG; Papageorgiou, AA | 1 |
| Aldrete-Velasco, J; Casanova, JM; Martínez, P; Mejía, P | 1 |
| Cantral, KA; Jungnickel, PW; Maloley, PA | 1 |
| Betteridge, DJ; Bhatnager, D; Bing, RF; Durrington, PN; Evans, GR; Flax, H; Jay, RH; Lewis-Barned, N; Mann, J; Matthews, DR | 1 |
| Miettinen, TA; Vanhanen, H | 1 |
| Luimers, OR | 1 |
| Kesäniemi, YA; Miettinen, TA; Vanhanen, H | 1 |
| Inoue, N; Itoh, H; Kishino, B; Koga, N; Nakashima, Y; Nishide, T; Okamura, K; Saito, Y; Tatami, R; Teramoto, T | 1 |
| Arca, M; Calandra, S; Ciarrocchi, A; D'Alò, G; Descovich, GC; Fazio, S; Gaddi, A; Tiozzo, R | 1 |
| Iwado, S; Kishida, Y; Naito, A; Terahara, A; Tsujita, Y | 1 |
| Karayalçin, U; Miyamori, I; Takeda, R; Takeda, Y | 1 |
| Karayalçin, U; Miyamori, I; Morise, T; Takeda, R; Takeda, Y | 1 |
| Arntz, HR; Bönner, G; Kikis, D; Kirch, W; Klör, HU; Lederle, RM; Overlack, A; Steinmetz, A; Stumpe, KO | 1 |
| Miettinen, TA | 1 |
| Angelin, B; Berglund, L; Dallner, G; Elmberger, PG; Eriksson, M; Kalén, A; Lund, E; Reihnér, E | 1 |
| Betteridge, DJ; Jay, RH; Katz, M; McGarrigle, HH; Reckless, JP; Stirling, C; Sturley, RH | 1 |
| Angelin, B; Berglund, L; Bondjers, G; Eriksson, M; Fager, G; Olofsson, SO; Wiklund, O | 1 |
| Bard, JM; Douste-Blazy, P; Fruchart, JC; Parra, HJ | 1 |
| de Rooy, FW; Hoogerbrugge-vd Linden, N; Jansen, H; van Blankenstein, M | 1 |
| Hayashi, H; Ito, H; Kawamura, M; Miyazaki, S; Naito, C | 1 |
| Angelin, B; Berglund, L; Bondjers, G; Eriksson, M; Fager, G; Lindén, T; Olofsson, SO; Sjöberg, A; Wiklund, O | 1 |
| Birkenhäger, JC; Hoogerbrugge, N; Mol, MJ; Muls, E; Rustemeijer, C; Stalenhoef, AF; Van Dormaal, JJ | 1 |
| Kurota, M; Maeda, H; Matsuda, T; Miyaho, S; Morikawa, K; Nakai, T; Oida, K; Takahashi, S; Takai, H; Tamai, T | 1 |
| Beretta-Piccoli, C; Fragiacomo, C; Noseda, G; Riesen, WF; Saxenhofer, H; Weidmann, P; Wunderlin, R | 1 |
| Betteridge, DJ; Jay, RH; Rampling, MW | 1 |
| Ishii, K; Kawai, C; Kita, T; Kume, N; Mikami, A; Nagano, Y; Yokode, M | 1 |
| Reynolds, GA | 1 |
| Chiesa, G; Franceschini, G; Gianfranceschi, G; Sirtori, CR; Sirtori, M; Vaccarino, V | 1 |
| Saito, Y; Yoshida, S | 1 |
| Baba, S; Iwai, M; Iwatani, I; Kasama, T; Kazumi, T; Morita, S; Yoshino, G | 1 |
| Fujita, H; Itoh, H; Kajinami, K; Kamon, N; Mabuchi, H; Michishita, I; Takeda, M; Takeda, R; Wakasugi, T | 1 |
| Goto, Y; Hata, Y; Homma, Y; Nakaya, N; Shigematsu, H; Tamachi, H | 1 |
| Yamamoto, A; Yamamura, T; Yokoyama, S | 1 |
| Baba, S; Iwai, M; Iwatani, I; Kasama, T; Kazumi, T; Matsuba, K; Matsushita, M; Otsuki, M; Yoshino, G | 1 |
| Hayashi, H; Ito, H; Kawamura, M; Naito, C | 1 |
| Fujita, H; Kajinami, K; Koizumi, J; Mabuchi, H; Michishita, I; Takeda, M; Takeda, R; Takegoshi, T; Ueda, K; Wakasugi, T | 1 |
5 review(s) available for pravastatin and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Early initiation of statin treatment in children with familial hypercholesterolaemia.
Topics: Atherosclerosis; Child; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pravastatin; Treatment Outcome | 2015 |
A meta-analysis to evaluate the efficacy of statins in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Triglycerides | 2007 |
Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.
Topics: Alleles; Apolipoproteins A; Apolipoproteins E; Double-Blind Method; Female; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Pravastatin | 1995 |
Pravastatin: a new drug for the treatment of hypercholesterolemia.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug Interactions; Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Pravastatin | 1992 |
[Research and development of pravastatin].
Topics: Animals; Arteriosclerosis; Chemical Phenomena; Chemistry, Physical; Drug Stability; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver; Molecular Structure; Penicillium; Pravastatin; Streptomyces | 1991 |
34 trial(s) available for pravastatin and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Statin therapy and secretory phospholipase A₂ in children with heterozygous familial hypercholesterolemia.
Topics: Adolescent; Biomarkers; C-Reactive Protein; Carotid Intima-Media Thickness; Child; Double-Blind Method; Female; Follow-Up Studies; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Phospholipases A2, Secretory; Pravastatin; Predictive Value of Tests | 2013 |
Ten-year follow-up after initiation of statin therapy in children with familial hypercholesterolemia.
Topics: Adolescent; Carotid Intima-Media Thickness; Child; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Linear Models; Lipids; Male; Pravastatin | 2014 |
Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood.
Topics: Adolescent; Adult; Age Factors; Biomarkers; Child; Dehydroepiandrosterone; Double-Blind Method; Estradiol; Female; Follicle Stimulating Hormone, Human; Gonadal Steroid Hormones; Gonadotropins, Pituitary; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Luteinizing Hormone; Male; Netherlands; Pravastatin; Risk Assessment; Risk Factors; Sex Factors; Testosterone; Time Factors; Treatment Outcome; Young Adult | 2015 |
Pharmacokinetics and pharmacodynamics of pravastatin in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Area Under Curve; Child; Cholesterol, HDL; Cholesterol, LDL; Chromatography, High Pressure Liquid; Female; Humans; Hyperlipoproteinemia Type II; Male; Pravastatin; Spectrometry, Mass, Electrospray Ionization; Triglycerides | 2003 |
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial.
Topics: Adolescent; Carotid Artery Diseases; Child; Cholesterol, LDL; Double-Blind Method; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Pravastatin; Prospective Studies; Ultrasonography | 2004 |
Low-density lipoprotein receptor genotype and response to pravastatin in children with familial hypercholesterolemia: substudy of an intima-media thickness trial.
Topics: Adolescent; Cardiovascular Diseases; Child; Coronary Vessels; Double-Blind Method; Female; Gene Deletion; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Placebos; Pravastatin; Receptors, LDL; Tunica Intima; Tunica Media | 2005 |
Serum noncholesterol sterols in children with heterozygous familial hypercholesterolemia undergoing pravastatin therapy.
Topics: Adolescent; Anticholesteremic Agents; Child; Cholestanol; Cholesterol; Desmosterol; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Phytosterols; Pravastatin; Sitosterols; Triglycerides | 2006 |
Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin.
Topics: Anticholesteremic Agents; Antigen-Antibody Complex; Apolipoproteins B; Autoantibodies; Child; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Immunoglobulin G; Immunoglobulin M; Lipoproteins, LDL; Male; Malondialdehyde; Pravastatin; Siblings | 2006 |
Atherogenic lipoprotein particle size and concentrations and the effect of pravastatin in children with familial hypercholesterolemia.
Topics: Adolescent; Anticholesteremic Agents; Child; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, HDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Particle Size; Pravastatin | 2008 |
Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy.
Topics: Alleles; Apolipoproteins A; Apolipoproteins E; Double-Blind Method; Female; Heterozygote; Homozygote; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Middle Aged; Phenotype; Polymorphism, Genetic; Pravastatin | 1995 |
Clinical evaluation of pravastatin in the treatment of type II hyperlipidemia in patients with non-insulin-dependent diabetes mellitus.
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus, Type 2; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin; Treatment Outcome | 1995 |
Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin.
Topics: Adult; Apolipoproteins B; Blood Platelets; Calcium; Cell Membrane; Cholesterol, HDL; Cholesterol, LDL; Cytosol; Double-Blind Method; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Membrane Fluidity; Middle Aged; Placebos; Pravastatin; Triglycerides; Viscosity | 1995 |
The RED-LIP study--pravastatin in primary isolated hypercholesterolemia--an open, prospective, multicenter trial.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Coronary Disease; Diet, Fat-Restricted; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Liver Function Tests; Male; Middle Aged; Pravastatin; Prospective Studies; Risk Factors; Triglycerides | 1994 |
Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia.
Topics: Adult; Aged; Alanine Transaminase; Aspartate Aminotransferases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Creatine Kinase; Drug Combinations; Female; Flushing; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Nausea; Niacin; Placebos; Pravastatin; Single-Blind Method; Triglycerides | 1994 |
Effect of hydroxymethylglutaryl-CoA reductase inhibitors on the functional properties of erythrocyte membranes.
Topics: Adolescent; Adult; Cholesterol; Erythrocyte Membrane; Female; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Membrane Fluidity; Membrane Lipids; Pravastatin; Simvastatin; Sodium-Potassium-Exchanging ATPase | 1993 |
Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
Topics: Adult; Aged; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; In Vitro Techniques; Lipids; Lipoproteins; Lipoproteins, LDL; Lovastatin; Male; Middle Aged; Oxidation-Reduction; Pravastatin; Simvastatin | 1993 |
Apolipoprotein E phenotypes in familial hypercholesterolaemia: importance for expression of disease and response to therapy.
Topics: Apolipoproteins E; Cholestyramine Resin; Double-Blind Method; Humans; Hyperlipoproteinemia Type II; Lipids; Phenotype; Pravastatin; Treatment Outcome | 1993 |
Apolipoprotein(a) polymorphism predicts the increase of Lp(a) by pravastatin in patients with familial hypercholesterolaemia treated with bile acid sequestration.
Topics: Adult; Aged; Apolipoproteins A; Bile Acids and Salts; Double-Blind Method; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoprotein(a); Male; Middle Aged; Phenotype; Polymorphism, Genetic; Pravastatin | 1993 |
Short-term efficacy and safety of pravastatin in 72 children with familial hypercholesterolemia.
Topics: Adolescent; Child; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Tolerance; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Pravastatin; Safety; Time Factors | 1996 |
Comparative effects of simvastatin and pravastatin on cholesterol synthesis in patients with primary hypercholesterolemia.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Liver; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Simvastatin; Treatment Outcome; Triglycerides | 1995 |
Effects of pravastatin on plasma and urinary mevalonate concentrations in subjects with familial hypercholesterolaemia: a comparison of morning and evening administration.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Hyperlipoproteinemia Type II; Male; Mevalonic Acid; Middle Aged; Pravastatin | 1996 |
Effect of a reduced-fat diet with or without pravastatin on glucose tolerance and insulin sensitivity in patients with primary hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Blood Glucose; Cholesterol; Diet, Fat-Restricted; Female; Glucose Tolerance Test; Humans; Hyperlipoproteinemia Type II; Insulin; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Triglycerides | 1996 |
Efficacy of pravastatin as a hypolipidemic agent in patients with polygenic hypercholesterolemia.
Topics: Adult; Cholesterol; Creatine Kinase; Female; Humans; Hyperlipoproteinemia Type II; Isoenzymes; Lipoproteins; Liver Function Tests; Male; Mexico; Middle Aged; Pravastatin; Prevalence; Prospective Studies; Socioeconomic Factors; Triglycerides | 1992 |
Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.
Topics: Adolescent; Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin; Treatment Outcome; Triglycerides | 1992 |
Regression of coronary atherosclerosis by combined LDL-apheresis and lipid-lowering drug therapy in patients with familial hypercholesterolemia: a multicenter study. The LARS Investigators.
Topics: Adult; Blood Component Removal; Cholesterol, LDL; Combined Modality Therapy; Coronary Angiography; Coronary Artery Disease; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Pravastatin; Probucol | 1992 |
[Effectiveness of pravastatin and bezafibrate in primary hypercholesterolemia].
Topics: Adult; Aged; Anticholesteremic Agents; Bezafibrate; Cholesterol; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Naphthalenes; Pravastatin; Triglycerides | 1991 |
Effects of pravastatin and cholestyramine on gonadal and adrenal steroid production in familial hypercholesterolaemia.
Topics: Adrenal Glands; Cholestyramine Resin; Female; Gonadal Steroid Hormones; Gonadotropins, Pituitary; Gonads; Humans; Hydrocortisone; Hyperlipoproteinemia Type II; Male; Pravastatin; Sex Hormone-Binding Globulin; Steroids | 1991 |
Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia.
Topics: Adult; Anticholesteremic Agents; Bile; Bile Acids and Salts; Cholesterol; Double-Blind Method; Enzyme Inhibitors; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Naphthalenes; Pravastatin | 1990 |
Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels.
Topics: Adult; Aged; Alanine Transaminase; Anticholesteremic Agents; Apolipoproteins; Aspartate Aminotransferases; Cholesterol, LDL; Cholestyramine Resin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Naphthalenes; Pravastatin; Randomized Controlled Trials as Topic; Triglycerides | 1990 |
The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia.
Topics: Anticholesteremic Agents; Bile Acids and Salts; Carrier Proteins; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxysteroid Dehydrogenases; Hyperlipoproteinemia Type II; Male; Membrane Glycoproteins; Naphthalenes; Pravastatin; Randomized Controlled Trials as Topic; Triglycerides | 1990 |
Therapeutic efficacy of the HMG-CoA-reductase inhibitor pravastatin in hyperlipoproteinaemia type II.
Topics: Anticholesteremic Agents; Apolipoproteins B; Apolipoproteins E; Apoproteins; Cholesterol, LDL; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Naphthalenes; Pravastatin; Triglycerides | 1990 |
Abnormalities of blood rheology in familial hypercholesterolaemia: effects of treatment.
Topics: Adult; Anticholesteremic Agents; Blood Viscosity; Cholestyramine Resin; Erythrocyte Aggregation; Erythrocyte Deformability; Female; Fibrinogen; Hematocrit; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged; Naphthalenes; Pravastatin; Rheology | 1990 |
Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolemia.
Topics: Apolipoproteins; Cholesterol; Female; Gemfibrozil; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Naphthalenes; Pravastatin; Time Factors; Triglycerides | 1989 |
The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins; Double-Blind Method; Drug Evaluation; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Naphthalenes; Pravastatin | 1987 |
65 other study(ies) available for pravastatin and Hyperlipoproteinemia Type II
| Article | Year |
|---|---|
Statin use in Australian children: a retrospective audit of four pediatric hospitals.
Topics: Adolescent; Atorvastatin; Australia; Child; Child, Preschool; Drug Utilization Review; Fluorobenzenes; Heptanoic Acids; Hospitals, Pediatric; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Infant; Kidney Diseases; Organ Transplantation; Pravastatin; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides | 2014 |
Urine-sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia.
Topics: Animals; Cell Differentiation; Cell Proliferation; Cholesterol, LDL; Female; Fibroblasts; Gene Expression Profiling; Hepatocytes; Humans; Hyperlipoproteinemia Type II; Induced Pluripotent Stem Cells; Karyotyping; Lipoproteins, LDL; Male; Mice; Mutation; Pravastatin; Proprotein Convertase 9; Proprotein Convertases; RNA, Messenger; Serine Endopeptidases; Urine | 2016 |
Statin-associated muscle symptoms and SLCO1B1 rs4149056 genotype in patients with familial hypercholesterolemia.
Topics: Age Factors; Body Mass Index; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypertension; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Myalgia; Odds Ratio; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2016 |
Long-term follow-up of statin treatment in a cohort of children with familial hypercholesterolemia: efficacy and tolerability.
Topics: Adolescent; Child; Child, Preschool; Cohort Studies; Female; Follow-Up Studies; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Pravastatin; Severity of Illness Index; Time Factors; Young Adult | 2011 |
HMG-CoA reductase inhibitor augments the serum total cholesterol-lowering effect of human adipose tissue-derived multilineage progenitor cells in hyperlipidemic homozygous Watanabe rabbits.
Topics: Adipose Tissue; Adult; Animals; Cell Lineage; Cholesterol; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Middle Aged; Pravastatin; Rabbits; Stem Cell Transplantation; Stem Cells; Young Adult | 2011 |
Statin-induced myositis migrans.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Myositis; Pravastatin; Pyrroles; Simvastatin; Time Factors | 2002 |
[After several years of statin therapy. Long-term prevention of cardiac death].
Topics: Adult; Age Factors; Anticholesteremic Agents; Child; Clinical Trials as Topic; Female; Follow-Up Studies; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Placebos; Pravastatin; Prognosis; Risk Factors; Time Factors | 2003 |
A boy with autosomal recessive hypercholesterolaemia.
Topics: Child; Cholesterol, LDL; Chromosome Disorders; Genes, Recessive; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mutation; Pravastatin; Receptors, LDL; Xanthogranuloma, Juvenile | 2004 |
Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: a prospective clinical follow-up study.
Topics: Achilles Tendon; Adolescent; Adrenocorticotropic Hormone; Carotid Arteries; Child; Child, Preschool; Female; Follow-Up Studies; Growth; Humans; Hyperlipoproteinemia Type II; Lipids; Male; Patient Compliance; Pravastatin; Prospective Studies; Sexual Development; Ultrasonography | 2005 |
Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment.
Topics: Animals; Apolipoproteins E; Arteriosclerosis; Brachiocephalic Trunk; Cholesterol, Dietary; Diet, Atherogenic; Dietary Fats; Drug Evaluation, Preclinical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Pravastatin; Rupture, Spontaneous | 2005 |
[Protective effects of pravastatin against atherosclerosis in children with familial hypercholesterolemia].
Topics: Child; Coronary Artery Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Pravastatin; Randomized Controlled Trials as Topic | 2005 |
Increased inflammatory markers in children with familial hypercholesterolaemia.
Topics: Adolescent; Anticholesteremic Agents; Biomarkers; Body Mass Index; C-Reactive Protein; CD40 Ligand; Child; Cholesterol, HDL; Cholesterol, LDL; Female; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Neopterin; Pravastatin; Siblings; Solubility | 2006 |
Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes.
Topics: Adolescent; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Child; Child, Preschool; Female; Genotype; Heart Transplantation; Humans; Hyperlipoproteinemia Type II; Liver-Specific Organic Anion Transporter 1; Male; Organic Anion Transporters; Polymorphism, Genetic; Pravastatin; Treatment Outcome | 2006 |
[The comparison in vitro the effects of pravastatin and quercetin on the selected structural parameters of membrane erythrocytes from patients with hypercholesterolemia].
Topics: Anticholesteremic Agents; Antioxidants; Electron Spin Resonance Spectroscopy; Erythrocyte Deformability; Erythrocyte Membrane; Female; Humans; Hyperlipoproteinemia Type II; In Vitro Techniques; Lipid Peroxidation; Male; Membrane Fluidity; Membrane Lipids; Middle Aged; Pravastatin; Quercetin; Thiobarbituric Acid Reactive Substances | 2007 |
Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.
Topics: Anticholesteremic Agents; Cell Line, Tumor; Clofibric Acid; DNA-Binding Proteins; Fenofibrate; Furin; Gene Expression Regulation, Enzymologic; Hepatocytes; Humans; Hydrocarbons, Fluorinated; Hyperlipoproteinemia Type II; Lipid Metabolism; Liver X Receptors; Orphan Nuclear Receptors; PPAR alpha; Pravastatin; Promoter Regions, Genetic; Proprotein Convertase 5; Proprotein Convertase 9; Proprotein Convertases; Receptors, Cytoplasmic and Nuclear; Receptors, LDL; Serine Endopeptidases; Sulfonamides; Up-Regulation | 2008 |
Regulation of apolipoprotein B secretion in hepatocytes from Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia.
Topics: Animals; Apolipoproteins B; Cells, Cultured; Cholesterol Esters; Disease Models, Animal; Enzyme-Linked Immunosorbent Assay; Female; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Liver; Male; Pravastatin; Rabbits; Receptors, LDL | 1995 |
Pravastatin modulates cholesteryl ester transfer from HDL to apoB-containing lipoproteins and lipoprotein subspecies profile in familial hypercholesterolemia.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol Esters; Female; Glycoproteins; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, HDL; Lipoproteins, LDL; Male; Pravastatin | 1995 |
Effects of pravastatin on lipid transfer protein and lecithin cholesterol acyltransferase in heterozygous familial hypercholesterolemia.
Topics: Adult; Aged; Carrier Proteins; Female; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged; Phosphatidylcholine-Sterol O-Acyltransferase; Pravastatin | 1993 |
In-vitro effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on non-hepatic LDL receptor activity: evidence of lack of stimulatory effect of pravastatin.
Topics: Female; Fibroblasts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Hyperlipoproteinemia Type II; Lovastatin; Lymphocytes; Male; Pravastatin; Receptors, LDL | 1994 |
Clearance of chylomicron-like lipid emulsions is increased in normal rabbits but not in heterozygous Watanabe heritable hyperlipidaemic rabbits following treatment with cholestyramine or pravastatin.
Topics: Analysis of Variance; Animals; Bile Acids and Salts; Cholestyramine Resin; Chylomicrons; Fat Emulsions, Intravenous; Heterozygote; Hydroxymethylglutaryl CoA Reductases; Hyperlipoproteinemia Type II; Metabolic Clearance Rate; Pravastatin; Rabbits | 1994 |
Cholesterol malabsorption caused by sitostanol ester feeding and neomycin in pravastatin-treated hypercholesterolaemic patients.
Topics: Anticholesteremic Agents; Cholesterol; Drug Therapy, Combination; Female; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intestinal Absorption; Male; Middle Aged; Neomycin; Pravastatin; Sitosterols | 1994 |
Effects of selective LDL-apheresis and pravastatin therapy on platelet function in familial hypercholesterolaemia.
Topics: Adult; Blood Component Removal; Blood Platelets; Combined Modality Therapy; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Male; Middle Aged; Platelet Aggregation; Platelet Count; Pravastatin; Time Factors | 1994 |
Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia.
Topics: Adult; Aged; Bezafibrate; Cholesterol, Dietary; Combined Modality Therapy; Female; Fenofibrate; Fibrinogen; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin | 1993 |
Accumulation of "small dense" low density lipoproteins (LDL) in a homozygous patients with familial defective apolipoprotein B-100 results from heterogenous interaction of LDL subfractions with the LDL receptor.
Topics: Adolescent; Adult; Apolipoprotein B-100; Apolipoproteins B; Base Sequence; Child; Cholesterol; DNA Primers; Female; Fibroblasts; Genetic Carrier Screening; Homozygote; Humans; Hyperlipoproteinemia Type II; Lipoproteins; Lipoproteins, LDL; Male; Middle Aged; Molecular Sequence Data; Pedigree; Polymerase Chain Reaction; Pravastatin; Receptors, LDL; Skin; Triglycerides | 1993 |
Reduction of lipoprotein(a) by LDL-apheresis using a dextran sulfate cellulose column in patients with familial hypercholesterolemia.
Topics: Adolescent; Adult; Apolipoproteins B; Blood Component Removal; Cellulose; Cholesterol, LDL; Dextran Sulfate; Heterozygote; Homozygote; Humans; Hyperlipoproteinemia Type II; Lipoprotein(a); Male; Pravastatin | 1993 |
Improvement of atherosclerosis and stiffness of the thoracic descending aorta with cholesterol-lowering therapies in familial hypercholesterolemia.
Topics: Adult; Anticholesteremic Agents; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Echocardiography, Transesophageal; Elasticity; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin; Probucol; Reproducibility of Results | 1996 |
Therapy with HMG CoA reductase inhibitors: characteristics of the long-term permanence of hypocholesterolemic activity.
Topics: Cholesterol; Cholesterol, LDL; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Lovastatin; Male; Middle Aged; Pravastatin; Simvastatin; Time Factors | 1995 |
Intima-media thickness after cholesterol lowering in familial hypercholesterolemia. A three-year ultrasound study of common carotid and femoral arteries.
Topics: Anticholesteremic Agents; Carotid Artery, Common; Cholesterol; Cholestyramine Resin; Female; Femoral Artery; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Tunica Intima; Tunica Media; Ultrasonography | 1995 |
Plasma mevalonic acid, an index of cholesterol synthesis in vivo, and responsiveness to HMG-CoA reductase inhibitors in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Coronary Disease; Enzyme Inhibitors; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Lovastatin; Male; Mevalonic Acid; Middle Aged; Pravastatin; Pyrroles; Simvastatin | 1996 |
Effects of two different HMG-CoA reductase inhibitors on thromboxane production in type IIA hypercholesterolemia.
Topics: Anticholesteremic Agents; Cholesterol; Enzyme Inhibitors; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lipids; Male; Middle Aged; Pravastatin; Thromboxane B2 | 1996 |
Comment on: effect of pravastatin sodium and simvastatin on plasma fibrinogen level and blood rheology in type II hyperlipoproteinemia.
Topics: Anticholesteremic Agents; Fibrinogen; Follow-Up Studies; Hemorheology; Humans; Hyperlipoproteinemia Type II; Lovastatin; Pravastatin; Simvastatin | 1996 |
[Pravastatin increases the activity pf the LDL receptors in lymphocytes of individuals with heterozygous familial hypercholesterolemia].
Topics: Adult; Anticholesteremic Agents; Apolipoproteins A; Apolipoproteins B; Female; Humans; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Receptors, LDL | 1997 |
Effects of pravastatin on cholesterol metabolism of cholesterol-fed heterozygous WHHL rabbits.
Topics: Animals; Anticholesteremic Agents; Cholesterol; Cholesterol, Dietary; Heterozygote; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Immunohistochemistry; Intestinal Absorption; Liver; Phytosterols; Polymerase Chain Reaction; Pravastatin; Rabbits; Receptors, LDL; RNA, Messenger | 1998 |
Low-density lipoprotein receptor genotype-dependent response to cholesterol lowering by combined pravastatin and cholestyramine in familial hypercholesterolemia.
Topics: Adult; Aged; Anion Exchange Resins; Anticholesteremic Agents; Bile; Cholestyramine Resin; Drug Therapy, Combination; Female; Genotype; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin; Receptors, LDL; Treatment Outcome | 1998 |
Hypocholesterolemic effect of pravastatin is associated with increased content of antioxidant vitamin-E in cholesterol fractions.
Topics: Adult; Aged; Anticholesteremic Agents; Antioxidants; Cholesterol; Cholesterol, LDL; Female; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin; Vitamin E | 1998 |
Effects of pravastatin on thoracic aortic atherosclerosis in patients with heterozygous familial hypercholesterolemia.
Topics: Adult; Age Factors; Aged; Anticholesteremic Agents; Aorta, Thoracic; Arteriosclerosis; Cholesterol, LDL; Female; Follow-Up Studies; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin; Treatment Outcome; Ultrasonography | 1998 |
Combination treatment with troglitazone, an insulin action enhancer, and pravastatin, an inhibitor of HMG-CoA reductase, shows a synergistic effect on atherosclerosis of WHHL rabbits.
Topics: Animals; Aorta, Thoracic; Arteriosclerosis; Blood Glucose; Cholesterol, LDL; Chromans; Coronary Vessels; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Glucose Tolerance Test; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperinsulinism; Hyperlipoproteinemia Type II; Hypoglycemic Agents; Insulin Resistance; Male; Pravastatin; Rabbits; Thiazoles; Thiazolidinediones; Troglitazone; Xanthomatosis | 1999 |
Statins and C-reactive protein.
Topics: C-Reactive Protein; Female; Humans; Hyperlipidemias; Hyperlipoproteinemia Type II; Hypolipidemic Agents; Male; Middle Aged; Pravastatin; Randomized Controlled Trials as Topic; Simvastatin | 1999 |
Two different types of exercise-induced muscle pain without myopathy and CK-elevation during HMG-Co-enzyme-A-reductase inhibitor treatment.
Topics: Adolescent; Adult; Creatine Kinase; Dose-Response Relationship, Drug; Exercise; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle Cramp; Muscle, Skeletal; Pain; Pravastatin; Prognosis; Risk Assessment; Simvastatin; Sports | 1999 |
Double filtration plasmapheresis maintains normal adhesion molecule levels.
Topics: Anticholesteremic Agents; Arteriosclerosis; Biomarkers; Cell Adhesion Molecules; Cholesterol; Disease Progression; Endothelium, Vascular; Filtration; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Hyperlipoproteinemia Type II; Intercellular Adhesion Molecule-1; Myocardial Ischemia; Peripheral Vascular Diseases; Plasmapheresis; Pravastatin; Thrombomodulin; Vascular Cell Adhesion Molecule-1; von Willebrand Factor | 1998 |
Opposite effects on serum cholesteryl ester transfer protein levels between long-term treatments with pravastatin and probucol in patients with primary hypercholesterolemia and xanthoma.
Topics: Achilles Tendon; Adult; Aged; Anticholesteremic Agents; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Glycoproteins; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Muscular Diseases; Pravastatin; Probucol; Tomography, X-Ray Computed; Treatment Outcome; Triglycerides; Xanthomatosis | 1999 |
Statin induced myopathy does not show up in MIBI scintigraphy.
Topics: Adult; Anticholesteremic Agents; Atorvastatin; Breast Neoplasms; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Indoles; Lovastatin; Male; Middle Aged; Muscle, Skeletal; Muscular Diseases; Pain; Pravastatin; Pyridines; Pyrroles; Radionuclide Imaging; Radiopharmaceuticals; Simvastatin; Technetium Tc 99m Sestamibi | 2001 |
Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3.
Topics: Adult; Aged; Analysis of Variance; Anticholesteremic Agents; Apolipoprotein E3; Apolipoprotein E4; Apolipoproteins; Apolipoproteins E; Chi-Square Distribution; Dose-Response Relationship, Drug; Female; Humans; Hyperlipoproteinemia Type II; Japan; Lipids; Male; Middle Aged; Phenotype; Pravastatin | 2001 |
Atorvastatin plus pravastatin for the treatment of heterozygous familial hypercholesterolaemia--a pilot study.
Topics: Analysis of Variance; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Pilot Projects; Pravastatin; Prospective Studies; Pyrroles; Treatment Outcome | 2001 |
Pravastatin and lovastatin similarly reduce serum cholesterol and its precursor levels in familial hypercholesterolaemia.
Topics: Adult; Aged; Cholesterol; Cholesterol, LDL; Desmosterol; Female; Humans; Hyperlipoproteinemia Type II; Isomerism; Lovastatin; Male; Middle Aged; Phytosterols; Pravastatin; Sitosterols; Triglycerides | 1992 |
[The treatment of familial hypercholesterolemia].
Topics: Humans; Hyperlipoproteinemia Type II; Pravastatin; Protein Binding | 1992 |
Pravastatin lowers serum cholesterol, cholesterol-precursor sterols, fecal steroids, and cholesterol absorption in man.
Topics: Adult; Cholesterol; Feces; Female; Humans; Hyperlipoproteinemia Type II; Ileum; Intestinal Absorption; Male; Middle Aged; Pravastatin; Steroids; Sterols | 1992 |
Pravastatin in heterozygous familial hypercholesterolemia: low-density lipoprotein (LDL) cholesterol-lowering effect and LDL receptor activity on skin fibroblastS.
Topics: Cholesterol, LDL; Female; Fibroblasts; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins, LDL; Male; Middle Aged; Pravastatin; Receptors, Cell Surface; Receptors, Lipoprotein; Regression Analysis; Skin | 1991 |
Influence of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on corticosteroid metabolism in patients with heterozygous familial hypercholesterolemia.
Topics: Adrenal Cortex Hormones; Cholesterol; Female; Heterozygote; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin; Tetrahydrocortisol; Tetrahydrocortisone | 1991 |
Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor pravastatin on urinary 6 beta-hydroxycortisol excretion: a preliminary study.
Topics: Adult; Cholesterol; Female; Humans; Hydrocortisone; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Pravastatin | 1991 |
Inhibition of cholesterol absorption by HMG-CoA reductase inhibitor.
Topics: Cholesterol, Dietary; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Intestinal Absorption; Lovastatin; Naphthalenes; Pravastatin | 1991 |
Effects of pravastatin and cholestyramine on products of the mevalonate pathway in familial hypercholesterolemia.
Topics: Adult; Aged; Cholesterol; Cholestyramine Resin; Dolichols; Drug Therapy, Combination; Female; Humans; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Mevalonic Acid; Middle Aged; Pravastatin; Ubiquinone | 1991 |
Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoproteins A; Cholestyramine Resin; Coronary Disease; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Naphthalenes; Pravastatin; Receptors, LDL | 1990 |
Effect of pravastatin, an HMG CoA reductase inhibitor, and cholestyramine, a bile acid sequestrant, on lipoprotein particles defined by their apolipoprotein composition.
Topics: Adult; Aged; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein C-III; Apolipoproteins; Apolipoproteins A; Apolipoproteins B; Apolipoproteins C; Apolipoproteins E; Bile Acids and Salts; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Cholestyramine Resin; Drug Evaluation; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipoproteinemia Type II; Lipid Metabolism; Lipoproteins; Male; Middle Aged; Naphthalenes; Pravastatin; Random Allocation; Triglycerides | 1990 |
The effect of pravastatin in relation to low density lipoprotein receptor activity.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Heterozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Middle Aged; Naphthalenes; Pravastatin; Receptors, LDL; Triglycerides | 1990 |
[A case of familial hypercholesterolemia associated with nephrotic syndrome].
Topics: Cholestyramine Resin; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Middle Aged; Naphthalenes; Nephrotic Syndrome; Pravastatin; Prednisolone; Probucol | 1990 |
Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (Pravastatin) and cholestyramine.
Topics: Animals; Anticholesteremic Agents; Cholestyramine Resin; Heptanoic Acids; Heterozygote; Hyperlipoproteinemia Type II; Liver; Male; Naphthalenes; Pravastatin; Rabbits; Receptors, LDL; RNA, Messenger | 1989 |
Rational therapy of familial hypercholesterolemia.
Topics: Animals; Anticholesteremic Agents; Cholestyramine Resin; Gene Expression Regulation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Naphthalenes; Pravastatin; Rabbits; Receptors, LDL | 1989 |
[Recent trend in the research of hyperlipidemia in Japan. Treatment of refractory hyperlipidemia].
Topics: Anticholesteremic Agents; Bezafibrate; Blood Component Removal; Cholesterol; Drug Therapy, Combination; Heptanoic Acids; Humans; Hyperlipoproteinemia Type I; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type V; Hyperlipoproteinemias; Naphthalenes; Pravastatin; Probucol; Triglycerides | 1989 |
Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia.
Topics: Apolipoproteins A; Apolipoproteins B; Apoproteins; Cholesterol, HDL; Cholesterol, LDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Lipoproteins, VLDL; Male; Naphthalenes; Pravastatin; Triglycerides | 1986 |
Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Female; Heptanoic Acids; Heterozygote; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged; Naphthalenes; Phospholipids; Pravastatin | 1987 |
Escape phenomenon occurs by lowering cholesterol with a hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitor in patients with familial hypercholesterolemia.
Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Dose-Response Relationship, Drug; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent; Hyperlipoproteinemia Type II; Lipoproteins; Male; Middle Aged; Naphthalenes; Pravastatin | 1988 |
Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Female; Heptanoic Acids; Humans; Hyperlipoproteinemia Type II; Lipids; Lipoproteins; Male; Middle Aged; Naphthalenes; Phospholipids; Pravastatin; Triglycerides | 1988 |
Activity of low-density lipoprotein receptors as estimated from concentrations of apolipoprotein B and C-II in serum.
Topics: Apolipoprotein C-II; Apolipoproteins; Apolipoproteins B; Apolipoproteins C; Cholesterol; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipids; Male; Middle Aged; Naphthalenes; Pravastatin; Receptors, LDL | 1988 |
Effects of CS-514 (eptastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipid and apolipoprotein levels in heterozygous familial hypercholesterolemic patients treated by low density lipoprotein (LDL)-apheresis.
Topics: Adult; Anticholesteremic Agents; Apolipoproteins; Blood Component Removal; Cholesterol; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Lipoproteins, LDL; Male; Middle Aged; Naphthalenes; Phospholipids; Pravastatin | 1988 |